Clinical trial
4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic…
NCT00003853 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003853 |
|---|---|
| Title | 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis |
| Official title | Phase II Trial of 4'-IODO-4'-Deoxydoxorubicin in Primary Amyloidosis (AL) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | 4'-iodo-4'-deoxydoxorubicin |
| Enrollment | 45 |
| Start date | Apr 1, 1999 |
| Primary completion | Aug 1, 2000 |
| Completion | Aug 1, 2001 |
| First posted | Jul 16, 2004 |
| Last update posted | Nov 12, 2012 |
| Countries | Italy, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: